Report: UnitedHealth picks up healthcare payments company Equian in $3.2B deal
Indianapolis-based Equian processes more than $50o billion in healthcare claims annually and works with nine out of the top 10 healthcare payers.
Anthem acquires behavioral health company Beacon Health Options
Beacon Health serves more than 40 million individuals across the country, including 3 million patients in" risk-based behavioral programs."
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Eli Lilly to preserve limited patient access to cancer drug Lartruvo after withdrawing it
The planned withdrawal follows the January failure of a Phase III trial to back up the study used for Lartruvo's accelerated approval. Following the announcement, the FDA and EMA recommended no new patients receive the drug.
Anthem inks novel partnership to link Indiana Medicaid patients to free legal services
Through a grant to the Indiana Legal Services, Anthem has expanded access to free legal services to all Medicaid patients in 18 counties in Central Indiana to assist with housing, employment and child support issues.
Indiana startup raises $2.5M for healthcare collaboration platform
The company, Olio, plans on using the funding to scale its technology, expand across the country and grow its marketing, engineering and customer success teams.
Lilly’s lower-cost insulin Humalog still too expensive, senator says
Sen. Dick Durbin, D-Illinois, was also among four signatories to a letter to FDA Commissioner Scott Gottlieb calling on the agency to speed up approvals of generic versions of insulin products.
presented by
These Are the Top-Rated Autism Therapy Centers in Texas
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
Lilly to introduce lower-priced version of insulin product Humalog
The new version, sold under its generic name, would be priced 50 percent lower than the branded version, at $137.35 per vial or $265.20 for a five-pack of pens.
Anthem to cut ties early with Express Scripts with launch of new internal PBM
Anthem, which has nearly 40 million members, has moved up the timeline on the development and launch of its own PBM known as IngenioRx, cutting ties with Express Scripts in the process.
FDA, EMA recommend no new patients start Lilly sarcoma drug after trial flops
Lilly announced last week that the Phase III confirmatory trial for Lartruvo in soft-tissue sarcomas failed to confirm the benefit seen in the Phase II study that led to its accelerated approval.
Lilly cancer drug with accelerated approval fails in confirmatory trial
A Phase III trial of Lartruvo, which won accelerated approval for soft-tissue sarcoma in 2016, failed to confirm an overall survival benefit.
presented by
Price Transparency is the New North in the PBM World
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Lilly to acquire Loxo Oncology for $8B
Loxo's shares were up 65 percent on the news. The company won FDA accelerated approval on Nov. 26 for its tissue-agnostic cancer drug, Vitrakvi.
Report: Anthem nabs Google, Amazon vet as head of its new AI group
Most recently, Udi Manber has served as a healthcare researcher and faculty member at the National Institutes of Health and at UC San Francisco.
Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer
Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.
Karuna Pharmaceuticals raises $42 million in Series A funding round
The company plans to use the financing to support development of its drug, KarXT, in schizophrenia and indications like pain.
Anthem will buy palliative care provider Aspire Health
Financial terms of the deal, which expected to close in the third quarter of this year, were not disclosed.